In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies

References

• Slukvin II. Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells. Blood. 2013;122(25):4035–15. doi:10.1182/blood-2013-07-474825.
   PubMed Web of Science ®Google Scholar
• Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood. 2009;114(17):3513–3523. doi:10.1182/blood-2009-03-191304.
   PubMed Web of Science ®Google Scholar
• Vo LT, Daley GQ. De Novo generation of HSCs from somatic and pluripotent stem cell sources. Blood. 2015;125(17):2641–2648. doi:10.1182/blood-2014-10-570234.
   PubMed Web of Science ®Google Scholar
• Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008;132(4):661–680. doi:10.1016/j.cell.2008.02.008.
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Ditadi A, Clarke RL, Keller G. Defining the path to hematopoietic stem cells. Nat Biotechnol. 2013;31(5):416–418. doi:10.1038/nbt.2571.
   PubMed Web of Science ®Google Scholar
• Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928–933. doi:10.1038/nbt.2678.
   PubMed Web of Science ®Google Scholar
• Kennedy M, Awong G, Sturgeon C, Ditadi A, LaMotte-Mohs R, Zúñiga-Pflücker J, Keller G. T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep. 2012;2(6):1722–1735. doi:10.1016/j.celrep.2012.11.003.
   PubMed Web of Science ®Google Scholar
• Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S, Taghon T, Moore HD, Leclercq G, Langerak AW, Kerre T, et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol. 2009;182(11):6879–6888. doi:10.4049/jimmunol.0803670.
   PubMed Web of Science ®Google Scholar
• Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S-I, Koseki H, Kawamoto H. Regeneration of human tumor antigen-specific T cells from iPscs derived from mature CD8 + T Cells. Cell Stem Cell. 2013;12(1):31–36. doi:10.1016/j.stem.2012.12.006.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12(1):114–126. doi:10.1016/j.stem.2012.11.002.
   PubMed Web of Science ®Google Scholar
• Iriguchi S, Yasui Y, Kawai Y, Arima S, Kunitomo M, Sato T, Ueda T, Minagawa A, Mishima Y, Yanagawa N, et al. A clinically applicable and scalable method to regenerate T-cells from iPscs for off-the-shelf T-cell immunotherapy. Nat Commun. 2021;12(1):430. doi:10.1038/s41467-020-20658-3.
   PubMed Web of Science ®Google Scholar
• Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJN, Lee DA, Kaufman DS. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274–283. doi:10.5966/sctm.2012-0084.
   PubMed Web of Science ®Google Scholar
• Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, Miller JS, Geller MA, Kaufman DS. Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. Stem Cells. 2016;34(1):93–101. doi:10.1002/stem.2230.
   PubMed Web of Science ®Google Scholar
• Galat Y, Dambaeva S, Elcheva I, Khanolkar A, Beaman K, Iannaccone PM, Galat V. Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential. Stem Cell Res Ther. 2017;8(1):67. doi:10.1186/s13287-017-0519-0.
   PubMedGoogle Scholar
• Mesquitta WT, Wandsnider M, Kang H, Thomson J, Moskvin O, Suknuntha K, Slukvin II. UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells. Sci Rep. 2019;9(1):6622. doi:10.1038/s41598-019-43054-4.
   PubMedGoogle Scholar
• Kitayama S, Zhang R, Liu T-Y, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, et al. Cellular adjuvant properties, direct cytotoxicity of re-differentiated Vα24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Rep. 2016;6(2):213–227. doi:10.1016/j.stemcr.2016.01.005.
   PubMed Web of Science ®Google Scholar
• Carpenter L, Malladi R, Yang C-T, French A, Pilkington KJ, Forsey RW, Sloane-Stanley J, Silk KM, Davies TJ, Fairchild PJ, et al. Human induced pluripotent stem cells are capable of B-cell lymphopoiesis. Blood. 2011;117(15):4008–4011. doi:10.1182/blood-2010-08-299941.
   PubMed Web of Science ®Google Scholar
• French A, Yang C-T, Taylor S, Watt SM, Carpenter L. Human induced pluripotent stem cell-derived B lymphocytes express sIgm and can be generated via a hemogenic endothelium intermediate. Stem Cells Dev. 2015;24(9):1082–1095. doi:10.1089/scd.2014.0318.
   PubMed Web of Science ®Google Scholar
• Vanhee S, De Mulder K, Van Caeneghem Y, Verstichel G, Van Roy N, Menten B, Velghe I, Philippe J, De Bleser D, Lambrecht BN, et al. In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis. Haematologica. 2015;100(2):157–166. doi:10.3324/haematol.2014.112144.
   PubMed Web of Science ®Google Scholar
• Abed S, Tubsuwan A, Chaichompoo P, Park IH, Pailleret A, Benyoucef A, Tosca L, De Dreuzy E, Paulard A, Granger-Locatelli M, et al. Transplantation of Macaca cynomolgus Ips-derived hematopoietic cells in NSG immunodeficient mice. Haematologica. 2015;100(10):e428–31. doi:10.3324/haematol.2015.127373.
   PubMed Web of Science ®Google Scholar
• Traver D. Going with the flow: how shear stress signals the emergence of adult hematopoiesis. J Exp Med. 2015;212(5):600. doi:10.1084/jem.2125insight4.
   PubMed Web of Science ®Google Scholar
• Schuelke MR, Wongthida P, Thompson J, Kottke T, Driscoll CB, Huff AL, Shim KG, Coffey M, Pulido J, Evgin L, et al. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. j Immunotherapy Cancer. 2019;7(1):188. doi:10.1186/s40425-019-0673-2.
   PubMedGoogle Scholar
• Sharifzad F, Mardpour S, Mardpour S, Fakharian E, Taghikhani A, Sharifzad A, Kiani S, Heydarian Y, Łos MJ, Azizi Z, et al. HSP70/IL-2 treated NK cells effectively cross the blood brain barrier and target tumor cells in a rat model of induced glioblastoma multiforme (GBM). Int J Mol Sci. 2020;21(7):2263. doi:10.3390/ijms21072263.
   PubMed Web of Science ®Google Scholar
• Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg K-J. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin Immunopathol. 2019;41(1):59–68. doi:10.1007/s00281-018-0721-x.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769–1781. doi:10.1016/j.ymthe.2017.06.012.
   PubMed Web of Science ®Google Scholar
• Backes CS, Friedmann KS, Mang S, Knörck A, Hoth M, Kummerow C. Natural killer cells induce distinct modes of cancer cell death: discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms. J Biol Chem. 2018;293(42):16348–16363. doi:10.1074/jbc.RA118.004549.
   PubMed Web of Science ®Google Scholar
• Prager I, Liesche C, van Ooijen H, Urlaub D, Verron Q, Sandström N, Fasbender F, Claus M, Eils R, Beaudouin J, et al. NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing. J Exp Med. 2019;216(9):2113–2127. doi:10.1084/jem.20181454.
   PubMed Web of Science ®Google Scholar
• O’ Reilly E, Tirincsi A, Logue SE, Szegezdi E. The janus face of death receptor signaling during tumor immunoediting. Front Immunol. 2016;7(446). doi:10.3389/fimmu.2016.00446.
   PubMedGoogle Scholar
• Belizario JE, Neyra JM, Setubal Destro Rodrigues MF. When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection. Innate Immun. 2018;24(8):452–465. doi:10.1177/1753425918800200.
   PubMed Web of Science ®Google Scholar
• Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047–5056. doi:10.1158/1078-0432.CCR-15-0685.
   PubMed Web of Science ®Google Scholar
• Mishukov A, Odinokova I, Mndlyan E, Kobyakova M, Abdullaev S, Zhalimov V, Glukhova X, Galat V, Galat Y, Senotov A, et al. ONC201-induced mitochondrial dysfunction, senescence-like phenotype, and sensitization of cultured BT474 human breast cancer cells to TRAIL. Int J Mol Sci. 2022;23(24):15551. doi:10.3390/ijms232415551.
   PubMed Web of Science ®Google Scholar
• Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Furlan SN, Vitanza NA, et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 2019;21(1):83–94. doi:10.1093/neuonc/noy145.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 2009;182(6):3530–3539. doi:10.4049/jimmunol.0802845.
   PubMed Web of Science ®Google Scholar
• Haspels HN, Rahman MA, Joseph JV, Gras Navarro A, Chekenya M. Glioblastoma stem-like cells are more susceptible than differentiated cells to natural killer cell lysis mediated through killer immunoglobulin-like receptors–human leukocyte antigen ligand mismatch and activation receptor–ligand interactions. Front Immunol. 2018;9:1345. doi:10.3389/fimmu.2018.01345.
   PubMed Web of Science ®Google Scholar
• Golan I, Rodriguez de la Fuente L, Costoya JA. NK cell-based glioblastoma immunotherapy. Cancers Basel. 2018;10(12):522. doi:10.3390/cancers10120522.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Sahu U, Zhou Y, Hogan AK, Sathyan KM, Bodner J, Huang J, Wong KA, Khalatyan N, Savas JN, et al. NOTCH1-driven UBR7 stimulates nucleotide biosynthesis to promote T cell acute lymphoblastic leukemia. Sci Adv. 2021;7(5). doi:10.1126/sciadv.abc9781.
   Web of Science ®Google Scholar
• Yu G. enrichplot: Visualization of Functional Enrichment Result. R Package Version 1.20.0. 2023. https://yulab-smu.top/biomedical-knowledge-mining-book/
   Google Scholar
• Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013;29(14):1830–1831. doi:10.1093/bioinformatics/btt285.
   PubMed Web of Science ®Google Scholar
• Carlson M, org.hs.eg.db: Genome wide annotation for Human. R Package Version 3.8.2. 2019. https://bioconductor.org/packages/release/data/annotation/html/org.Hs.eg.db.html
   Google Scholar
• Kolde R, pheatmap: Pretty Heatmaps R Package Version 1.0.12. 2019. https://cran.r-project.org/web/packages/pheatmap/index.html
   Google Scholar
• Team R Core. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2018. https://www.r-project.org
   Google Scholar
• Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016. doi:10.1007/978-3-319-24277-4_9.
   Google Scholar
• Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov. 2021;2(3):100141. doi:10.1016/j.xinn.2021.100141.
   Google Scholar
• Pituch KC, Zannikou M, Ilut L, Xiao T, Chastkofsky M, Sukhanova M, Bertolino N, Procissi D, Amidei C, Horbinski CM, et al. Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. Proc Natl Acad Sci U S A. 2021;118(9). doi:10.1073/pnas.2015800118.
   PubMed Web of Science ®Google Scholar
• Galat Y, Elcheva I, Dambaeva S, Katukurundage D, Beaman K, Iannaccone PM, Galat V. Application of small molecule CHIR99021 leads to the loss of hemangioblast progenitor and increased hematopoiesis of human pluripotent stem cells. Exp Hematol. 2018;65:38–48 e1. doi:10.1016/j.exphem.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, Tobin NP, Blake E, Seitz C, Thomas R, et al. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest. 2020;130(3):1185–1198. doi:10.1172/JCI128895.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cui L, Georgiev P, Singh L, Zheng Y, Yu Y, Grein J, Zhang C, Muise ES, Sloman DL, et al. Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncoimmunology. 2021;10(1):1896643. doi:10.1080/2162402X.2021.1896643.
   PubMed Web of Science ®Google Scholar
• Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M, Yin B, Huang J, Mao L, Lu Y, et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol. 2015;45(10):2886–2897. doi:10.1002/eji.201545480.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-0.
   PubMed Web of Science ®Google Scholar
• Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624–636. doi:10.1182/blood.2020007748.
   PubMed Web of Science ®Google Scholar
• Terren I, Orrantia A, Vitallé J, Zenarruzabeitia O, Borrego F. NK cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278. doi:10.3389/fimmu.2019.02278.
   PubMed Web of Science ®Google Scholar
• Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Bernal-Crespo V, Behymer MM, Knipp GT, Yun Y, Veronesi MC, et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Proc Natl Acad Sci U S A. 2021;118(45). doi:10.1073/pnas.2107507118.
   Web of Science ®Google Scholar
• Choi C, Finlay DK. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy. Stem Cell Res Ther. 2021;12(1):320. doi:10.1186/s13287-021-02377-8.
   PubMed Web of Science ®Google Scholar
• Frankel B, Longo SL, Kyle M, Canute GW, Ryken TC. Tumor Fas (APO-1/CD95) up-regulation results in increased apoptosis and survival times for rats with intracranial malignant gliomas. Neurosurgery. 2001;49(1):168–176. discussion 175-6. doi:10.1227/00006123-200107000-00026.
   PubMed Web of Science ®Google Scholar
• Xia S, Rosen EM, Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Res. 2005;65(12):5248–5255. doi:10.1158/0008-5472.CAN-04-4332.
   PubMed Web of Science ®Google Scholar
• Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, et al. CD95/Fas increases stemness in cancer cells by inducing a STAT1-dependent type i interferon response. Cell Rep. 2017;18(10):2373–2386. doi:10.1016/j.celrep.2017.02.037.
   PubMed Web of Science ®Google Scholar
• Drachsler M, Kleber S, Mateos A, Volk K, Mohr N, Chen S, Cirovic B, Tüttenberg J, Gieffers C, Sykora J, et al. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells. Cell Death Disease. 2016;7(4):e2209. doi:10.1038/cddis.2016.102.
   PubMedGoogle Scholar
• Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, et al. Adoptive transfer of IL13Rα2-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma. Mol Ther. 2018;26(4):986–995. doi:10.1016/j.ymthe.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Vodyanik MA, Bork JA, Thomson JA, Slukvin II. Human embryonic stem cell–derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood. 2005;105(2):617–626. doi:10.1182/blood-2004-04-1649.
   PubMed Web of Science ®Google Scholar
• Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee J-H, Tong L, Vodyanik M, Swanson S, Stewart R, Kyba M, et al. Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat Commun. 2014;5(1):4372. doi:10.1038/ncomms5372.
   PubMedGoogle Scholar
• Doulatov S, Vo L, Chou S, Kim P, Arora N, Li H, Hadland B, Bernstein I, Collins J, Zon L, et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell. 2013;13(4):459–470. doi:10.1016/j.stem.2013.09.002.
   PubMed Web of Science ®Google Scholar
• Cardona-Echeverry A, Prada-Arismendy J. Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patients’ prognosis. J Cancer Res Clin Oncol. 2020;146(12):3097–3109. doi:10.1007/s00432-020-03407-3.
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Ditadi A, Awong G, Kennedy M, Keller G. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells. Nat Biotechnol. 2014;32(6):554–561. doi:10.1038/nbt.2915.
   PubMed Web of Science ®Google Scholar
• D’Souza SS, Maufort J, Kumar A, Zhang J, Smuga-Otto K, Thomson J, Slukvin I. GSK3β inhibition promotes efficient myeloid and lymphoid hematopoiesis from non-human primate-induced pluripotent stem cells. Stem Cell Rep. 2016;6(2):243–256. doi:10.1016/j.stemcr.2015.12.010.
   PubMed Web of Science ®Google Scholar
• Barcia Durán JG, Lis R, Lu TM, Rafii S. In vitro conversion of adult murine endothelial cells to hematopoietic stem cells. Nat Protoc. 2018;13(12):2758–2780. doi:10.1038/s41596-018-0060-3.
   PubMed Web of Science ®Google Scholar
• Motazedian A, Bruveris FF, Kumar SV, Schiesser JV, Chen T, Ng ES, Chidgey AP, Wells CA, Elefanty AG, Stanley EG, et al. Multipotent RAG1+ progenitors emerge directly from haemogenic endothelium in human pluripotent stem cell-derived haematopoietic organoids. Nat Cell Biol. 2020;22(1):60–73. doi:10.1038/s41556-019-0445-8.
   PubMed Web of Science ®Google Scholar
• Vodyanik MA, Thomson JA, Slukvin II. Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood. 2006;108(6):2095–2105. doi:10.1182/blood-2006-02-003327.
   PubMed Web of Science ®Google Scholar
• Kessel KU, Bluemke A, Schöler HR, Zaehres H, Schlenke P, Dorn I. Emergence of CD43-expressing hematopoietic progenitors from human induced pluripotent stem cells. Transfus Med Hemother. 2017;44(3):143–150. doi:10.1159/000477357.
   PubMed Web of Science ®Google Scholar
• Diaz MF, Li N, Lee HJ, Adamo L, Evans SM, Willey HE, Arora N, Torisawa Y-S, Vickers DA, Morris SA, et al. Biomechanical forces promote blood development through prostaglandin E2 and the camp–PKA signaling axis. J Exp Med. 2015;212(5):665–680. doi:10.1084/jem.20142235.
   PubMed Web of Science ®Google Scholar
• Jing L, Tamplin OJ, Chen MJ, Deng Q, Patterson S, Kim PG, Durand EM, McNeil A, Green JM, Matsuura S, et al. Adenosine signaling promotes hematopoietic stem and progenitor cell emergence. J Exp Med. 2015;212(5):649–663. doi:10.1084/jem.20141528.
   PubMed Web of Science ®Google Scholar
• Kim PG, Nakano H, Das PP, Chen MJ, Rowe RG, Chou SS, Ross SJ, Sakamoto KM, Zon LI, Schlaeger TM, et al. Flow-induced protein kinase A–CREB pathway acts via BMP signaling to promote HSC emergence. J Exp Med. 2015;212(5):633–648. doi:10.1084/jem.20141514.
   PubMed Web of Science ®Google Scholar
• Vanuytsel K. Multi-modal profiling of human fetal liver hematopoietic stem cells reveals the molecular signature of engraftment. Nature Communications. 2022;13:1103. doi:10.1038/s41467-022-28616-x.
   PubMedGoogle Scholar
• Sugimura R. Derivation of hematopoietic stem and progenitor cells from human pluripotent stem cells. Methods Mol Biol. 2019;2005:37–41.
   PubMedGoogle Scholar
• Abe T, Uosaki H, Shibata H, Hara H, Sarentonglaga B, Nagao Y, Hanazono Y. Fetal sheep support the development of hematopoietic cells in vivo from human induced pluripotent stem cells. Exp Hematol. 2021;95:46–57.e8. doi:10.1016/j.exphem.2020.12.006.
   PubMed Web of Science ®Google Scholar
• Chester C, Fritsch K, Kohrt HE. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front Immunol. 2015;6:601. doi:10.3389/fimmu.2015.00601.
   PubMed Web of Science ®Google Scholar
• Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, et al. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020;22(8):1214–1225. doi:10.1093/neuonc/noaa047.
   PubMed Web of Science ®Google Scholar
• Qu Y, Bi JZ. [Killing effect of Robo1 targeted chimeric antigen receptor modified NK92 cells against glioma and neuroblastoma cells]. Zhonghua Yi Xue Za Zhi. 2018;98(11):860–866. doi:10.3760/cma.j.issn.0376-2491.2018.11.014.
   PubMedGoogle Scholar